Cargando…

Metronomic chemotherapy: changing the paradigm that more is better

The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Scharovsky, O.G., Mainetti, L.E., Rozados, V.R.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669231/
https://www.ncbi.nlm.nih.gov/pubmed/19370174
_version_ 1782166245146099712
author Scharovsky, O.G.
Mainetti, L.E.
Rozados, V.R.
author_facet Scharovsky, O.G.
Mainetti, L.E.
Rozados, V.R.
author_sort Scharovsky, O.G.
collection PubMed
description The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer.
format Text
id pubmed-2669231
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-26692312009-04-14 Metronomic chemotherapy: changing the paradigm that more is better Scharovsky, O.G. Mainetti, L.E. Rozados, V.R. Curr Oncol Medical Oncology The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer. Multimed Inc. 2009-03 /pmc/articles/PMC2669231/ /pubmed/19370174 Text en 2009 Multimed Inc.
spellingShingle Medical Oncology
Scharovsky, O.G.
Mainetti, L.E.
Rozados, V.R.
Metronomic chemotherapy: changing the paradigm that more is better
title Metronomic chemotherapy: changing the paradigm that more is better
title_full Metronomic chemotherapy: changing the paradigm that more is better
title_fullStr Metronomic chemotherapy: changing the paradigm that more is better
title_full_unstemmed Metronomic chemotherapy: changing the paradigm that more is better
title_short Metronomic chemotherapy: changing the paradigm that more is better
title_sort metronomic chemotherapy: changing the paradigm that more is better
topic Medical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669231/
https://www.ncbi.nlm.nih.gov/pubmed/19370174
work_keys_str_mv AT scharovskyog metronomicchemotherapychangingtheparadigmthatmoreisbetter
AT mainettile metronomicchemotherapychangingtheparadigmthatmoreisbetter
AT rozadosvr metronomicchemotherapychangingtheparadigmthatmoreisbetter